Asia Pacific loop-mediated isothermal amplification (LAMP) industry is projected to reach USD 237.3 million in 2024 on the back of rising burden of infectious diseases. Demand in the region is anticipated to increase at a CAGR of 5.7% throughout the forecast period, with total industry valuation reaching USD 409.8 million by 2034. The LAMP industry in Asia Pacific was valued at USD 223.2 million in 2023 and is poised to exhibit a Y-o-Y growth of 5.7% in 2024.
Asia Pacific Loop-mediated Isothermal Amplification Industry Statistics
Attributes | Details |
---|---|
Base Value in 2023 | USD 223.2 million |
Industry Size in 2024 | USD 237.3 million |
Industry Revenue in 2034 | USD 409.8 million |
Value CAGR (2024 to 2034) | 5.7% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Loop-mediated isothermal amplification is becoming a powerful DNA amplification tool as it offers multiple advantages over PCR and other methods. Its speed, simplicity, and cost-effectiveness are encouraging its adoption in applications like disease diagnosis and food testing.
The LAMP industry in APAC is witnessing steady growth, spurred by increasing infectious disease burden and innovations in the field of genomics and proteomics. Similarly, escalating demand for rapid and accurate diagnostic tests for infectious diseases is set to boost growth.
Growing awareness about the benefits of new technology for point-of-care testing and continuous innovations in technology are other key loop-mediated isothermal amplification industry growth factors. To benefit from this, leading players in loop-mediated isothermal amplification sector are constantly developing new assay kits and instruments.
Asia Pacific is also experiencing high demand for precision and personalized medicine. This will further boost growth of LAMP industry in the region. However, high costs, regulatory challenges, and approval processes for diagnostic products can act as an anchor to the industry growth.
The Asia Pacific loop-mediated isothermal amplification industry recorded a CAGR of 5.1% from 2019 to 2023. In comparison, a CAGR of 5.7% has been estimated for the target industry between 2024 and 2034, indicating a spike of 0.6% from the historical growth rate.
In Asia Pacific, the prevalence of foodborne illnesses has increased rapidly due to shifting eating habits and food adulteration. Ready-to-eat food (RTE) may carry bacteria like Salmonella, Escherichia coli, Shigella, Mycobacterium bovis, as well as toxins from Clostridium species and Staphylococcus Aureus. Such infected meat causes meat-borne diseases (MDBs), which are sometimes fatal.
With the constant rise in meat consumption, the demand for proper and effective diagnostics methods, such as loop-mediated isothermal amplification, has increased. This trend will continue as meat consumption is anticipated to grow significantly in the coming years.
Looking forward, the loop-mediated isothermal amplification future scope looks bright in Asia Pacific. This is due to widening usage of technology in applications like disease diagnosis, environmental testing, and animal husbandry. Subsequently, advances in instruments will bode well for the industry.
Zoonotic diseases pose a serious risk to human health as well as animals. Quick diagnostic techniques can aid in managing infectious diseases within herds. The rapid and easy nucleic acid amplification technique, loop-mediated isothermal amplification, has a significant window of opportunity for diagnosis of such infectious diseases in cattle.
Strategic collaborations are likely to persist, fueling the development of novel products. Moreover, manufacturers may find strategic collaborations as a proactive measure to navigate challenges and boost growth.
Increasing incidence of various bacterial and viral infections such as tuberculosis, malaria, pneumonia, influenza, and others is set to increase demand for loop-mediated isothermal amplification products. This is due to their ability to quickly and accurately detect these diseases.
Asia Pacific has been significantly affected by infectious diseases due to its dense population, high mobility, and varying levels of healthcare infrastructure. For instance, according to the World Health Organization (WHO), the region accounted for more than 60% of the global burden of tuberculosis (TB) cases in 2020.
To counter the growing disease burden, rapid diagnostic technologies and novel treatments are being used. This will continue to create growth prospects for the loop-mediated isothermal amplification sector in the region.
Organizations like the Asia Pacific Economic Cooperation (APEC) have recognized the critical role of diagnostic testing in addressing prevalence of infectious diseases. APEC member economies have prioritized collaboration in research and development, technology transfer, and capacity building to enhance diagnostic capabilities in the region.
Growing awareness about the benefits of innovative technology for point-of-care testing is another key factor boosting growth in Asia Pacific. Similarly, increasing government support will facilitate industry development in the region through 2034.
Demand for loop-mediated isothermal amplification is continuously increasing. However, regulatory challenges and approval processes for diagnostic products are limiting growth. Similarly, limited healthcare infrastructure and resources can reduce adoption in developing economies.
Governments across the APAC region have stringent regulatory frameworks governing the approval and commercialization of medical devices and diagnostic assays to ensure their safety, efficacy, and quality. These regulatory hurdles often result in delays in entry for diagnostic products.
In nations like India, the Central Drugs Standard Control Organization (CDSCO) regulates the approval and import of diagnostic kits and medical devices through a rigorous review process. Similarly, in China, the National Medical Products Administration (NMPA) checks the registration and regulation of medical devices, including diagnostic assays. It requires manufacturers to submit comprehensive documentation and conduct clinical evaluations to obtain approval.
The diversity of regulatory requirements across different countries within the Asia Pacific region complicates the process for manufacturers seeking to introduce assays to multiple industries simultaneously. Each country may have its own set of regulations, documentation requirements, and timelines for regulatory approval, leading to additional administrative burdens and resource allocation for manufacturers.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The LAMP industry size exhibits varying growth rates across different Asia Pacific countries. Thailand and India are set to record high CAGRs of 8.2% and 6.2%, respectively, through 2034.
Regional Analysis of LAMP Industry
Countries | Value CAGR |
---|---|
China | 4.8% |
Japan | 4.3% |
India | 6.2% |
Australia & New Zealand | 5.7% |
Thailand | 8.2% |
China dominates the Asia Pacific loop-mediated isothermal amplification industry, accounting for a value share of 27.9% in 2023. Over the next ten years, demand for these products in the country is set to record a CAGR of 4.8%.
Several factors are spurring the growth of China's loop-mediated isothermal amplification sector. These include a well-established healthcare infrastructure in the country, surging adoption of unique diagnostic technologies, and spike in infectious diseases.
Growing emphasis on early disease detection in China is compelling healthcare professionals to employ innovative diagnostic techniques. This will propel demand as it offers a simpler and faster alternative to polymerase chain reaction tests.
China is also leading when it comes to medical advancements in Asia Pacific. Several China-based players are striving to develop new instruments and kits for different applications. This will further improve China’s loop-mediated isothermal amplification industry share.
India is emerging as a highly lucrative pocket for manufacturers, owing to growing incidence of chronic & infectious diseases and favorable government support. It accounted for 19.8% of Asia Pacific industry share in 2023 and is set to record a robust CAGR of 6.2% through 2034.
In recent years, there has been a sharp rise in infectious diseases like malaria, TB, and dengue fever across India, and the trend is anticipated to persist through 2034. This, in turn, will uplift demand for rapid and accurate diagnostic techniques like LAMP.
The Government of India is striving to improve healthcare infrastructure and tackle infectious disease burden. This is anticipated to create lucrative growth opportunities for manufacturers in the nation.
The section below provides a detailed segmentation of loop-mediated isothermal amplification industry and offers deeper insights into top segments and their respective growth rate. This information can help companies act accordingly and strengthen their presence in lucrative regions.
Based on product, the reagents segment dominated the industry with a share of 47.3% in 2023. The microfluidic technology segment accounted for a prominent value share of 63.8% in 2023. Similarly, details about other leading segments are provided in this section.
Growth Outlook by Key Product
Product Type | Value CAGR |
---|---|
Instruments | 6.1% |
Kits | 6.9% |
Reagents | 4.5% |
Reagents dominated the Asia Pacific industry, accounting for a revenue share of 47.3% in 2023. Over the forecast period, a CAGR of 4.5% has been estimated for the same segment. This can be attributed to growing importance of reagents in LAMP procedures.
Numerous reagents, such as DNA polymerase, primers, and master mix, are required for conducting diagnostic tests. Their constant repetitive requirement is contributing to their industry dominance.
Different assays need specific primer mixes that can target a particular DNA sequence. Thus, as the application areas of technology widen, so will demand for reagents like primer mixes. This will continue to boost the target segment through 2034.
On the other hand, the kits segment is poised to register a higher CAGR of 6.9% during the assessment period. This is because they offer a user-friendly, affordable, and rapid way to perform tests.
Growth Outlook by Key Technology
Technology | Value CAGR |
---|---|
Micro-fluidic Technology | 4.8% |
Modern Microsystem Technology | 6.4% |
Advanced IR Technology | 8.4% |
Micro-fluidic technology remains widely popular in Asia Pacific, holding a value share of 63.8% in 2023. For the next ten years, a CAGR of 4.8% has been estimated for the same segment.
Increasing use of micro-fluidic technology due to its simplicity, fast speed, and accuracy over other technologies is boosting the segment. By using microfluidics, companies are able to create miniaturized devices that are ideal for point-of-care testing.
Growth Outlook by Key Application
Application | Value CAGR |
---|---|
Disease Diagnosis | 3.6% |
Environmental Inspection | 8.3% |
Food Hygiene | 10.2% |
Animal Husbandry | 5.7% |
Fisheries | 6.6% |
Disease diagnosis segment is anticipated to account for a prominent value share by 2034, recording a CAGR of 3.6%. This is attributable to increasing usage of assays for diagnosing various diseases due to its advantages like faster results and high specificity.
Growing prevalence of various infectious diseases is a major concern globally. LAMP is effective in diagnosis of these diseases. Moreover, its use in precision medicine is increasing its demand as a disease diagnostics tool.
Surging need for rapid diagnostics due to high incidence of diseases like malaria is set to play a key role in fueling demand. Similarly, growing awareness of the benefits of LAMP in disease detection than other methods like PCR will boost segment growth.
Growth Outlook by Key End-user
End-user | Value CAGR |
---|---|
Hospital Laboratories | 4.5% |
Academic & Research Institutes | 7.0% |
Pharmaceutical & Biotechnology Companies | 5.8% |
Diagnostic Laboratories | 3.4% |
Food Testing Laboratories | 8.7% |
Agricultural and Environmental Research Institutes | 10.6% |
Hospital laboratories are projected to hold a significant share of the Asia Pacific LAMP industry, registering a CAGR of 4.5%. This can be attributed to growing adoption of novel solutions in hospital laboratories for disease detection purposes.
LAMP has its major application in diagnosis of various infectious diseases. As a result, it is widely used in hospital laboratories due to its effectiveness. Moreover, due to the price-sensitive nature of Asian countries, people tend to prefer low-cost hospitals for the treatment of their medical conditions. This increases demand in hospital laboratories.
In the dynamic landscape of the loop-mediated isothermal amplification industry, companies are focusing on creating assays for different targets, including infectious diseases, genetic mutations, and foodborne pathogens. They are also putting efforts to integrate LAMP technology into microfluidic devices for more portable, rapid diagnostics.
Kits that are easy and simpler to use are making their entry into the industry. Similarly, strategies like partnerships, acquisitions, collaborations, and agreements are other loop-mediated isothermal amplification business strategies.
Majority of manufacturing giants are located in regions like North America and Europe. As these companies see opportunities in areas like Asia Pacific and the Middle East, they are striving to mark their presence in these regions.
Recent Developments
Date and Approach | Description |
---|---|
October 2022, New Product Launch | The United States-based Thermo Fisher Scientific Inc. showcased cutting-edge research and diagnostic technologies at the 2022 annual meeting and expo organized by the Association for Molecular Pathology (AMP) in the Phoenix Convention Center. During this event, Thermo Fisher introduced the Molecular Diagnostics Assay Developer Program for OEM partners. The company is striving to strengthen its presence in lucrative regions like India to boost its revenue. |
November 2021, New Product Launch |
Meridian Bioscience, Inc., headquartered in the United States, launched the Air-Dryable LAMP Mix and Air-Dryable RT-LAMP 1-Step Mix. These pioneering molecular master mixes are engineered for rapid isothermal amplification of nucleic acid sequences, catering to the development of point-of-care assays that remain stable at ambient temperatures. |
Attribute | Details |
---|---|
Estimated Size (2024) | USD 237.3 million |
Forecast Size (2034) | USD 409.8 million |
CAGR (2024 to 2034) | 5.7% |
Forecast Period | 2024 to 2034 |
Historical Data Available for | 2018 to 2023 |
Analysis | USD million for Value |
Key Regions Covered | East Asia and South Asia & Pacific |
Key Countries Covered | China, Japan, South Korea, India, Australia & New Zealand, Thailand, Vietnam, Philippines, Indonesia, Malaysia and Rest of South Asia & Pacific |
Key Segments Covered | Product, Technology, Application, Purpose, End-user and Region |
Key Companies Profiled | Eiken Chemical Co., Ltd.; New England Biolabs; HUMAN; Meridian Bioscience, Inc.; Thermo Fisher Scientific; Mast Group Ltd; Merck KGaA; Bio Rad Laboratories Inc. ; QIAGEN N.V; Optigene; NIPPON GENE CO., LTD; ZENOSTIC; Jena Bioscience GmbH; Excellgen, Inc; Hologic Inc. (Gen-Probe); LGC Ltd.; Abbott Laboratories, Inc. ; Yeasen Biotechnology (Shanghai) Co. Ltd.; highQu GmbH |
Report Coverage | Industry Forecast, Competition Intelligence, DROT Analysis, Industry Dynamics and Challenges, Strategic Growth Initiatives |
The industry is segregated into instruments, kits, and reagents. To get a broader picture of the industry, instruments are further classified into incubation systems, turbidimeters, agarose gel electrophoresis, and fluorescence measuring systems. A detailed analysis of sub-segments of reagents has also been added to the report, based on DNA polymerase, primer mix, master mix, DNA polymerase and primer mix, and dyes.
The industry includes three key technologies, namely, microfluidic technology, modern microsystem technology, and advanced IR technology.
Some of the leading applications include disease diagnosis, environmental inspection, food hygiene, animal husbandry, and fisheries. To get a clear picture of the diseases that can be diagnosed using LAMP, the segment is further divided into mycobacterium tuberculosis, SARS-CoV-2 (COVID-19), malaria, pneumonia, influenza, herpes, pertussis, and clostridium difficile infection.
The two main purposes are clinical use and research purpose.
Leading end-users in the industry include hospital laboratories, academic & research institutes, pharmaceutical & biotechnology companies, diagnostic laboratories, food testing laboratories, and agricultural & environmental research institutes.
Key countries of East Asia and South Asia & Pacific are covered.
Sales in Asia Pacific are set to total USD 237.3 million in 2024.
Demand is projected to increase at a 5.7% CAGR through 2034.
Asia Pacific industry size is set to reach USD 409.8 million by 2034.
China, Japan, India, Australia & New Zealand, and Thailand.
From 2019 to 2023, the industry recorded a 5.1% CAGR.
China is set to exhibit a 4.8% CAGR.
A powerful, low-cost DNA amplification technique.
Eiken Chemical Co., Ltd.
It is based on auto cycling and high DNA strand displacement activity.
A single-tube technique for DNA amplification.
1. Executive Summary 2. Industry Introduction, including Taxonomy and Industry Definition 3. Industry Trends and Success Factors, including Macro-economic Factors, Industry Dynamics, and Recent Industry Developments 4. Asia Pacific Industry Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections 5. Asia Pacific Industry Analysis 2019 to 2023 and Forecast 2024 to 2034 6. Asia Pacific Industry Analysis 2019 to 2023 and Forecast 2024 to 2034, by Product 6.1. Instruments 6.1.1. Incubation Systems 6.1.2. Turbidimeters 6.1.3. Agarose Gel 6.1.4. Electrophoresis 6.1.5. Fluorescence 6.1.6. Measuring Systems 6.2. Kits 6.3. Reagents 6.3.1. DNA Polymerase 6.3.2. Primer Mix 6.3.3. Master Mix 6.3.4. DNA Polymerase and Primer Mix 6.3.5. Dyes 6.3.6. Other 7. Asia Pacific Industry Analysis 2019 to 2023 and Forecast 2024 to 2034, by Technology 7.1. Micro-fluidic Technology 7.2. Modern Microsystem Technology 7.3. Advanced IR Technology 8. Asia Pacific Industry Analysis 2019 to 2023 and Forecast 2024 to 2034, by Application 8.1. Disease Diagnosis 8.1.1. Mycobacterium 8.1.2. Tuberculosis 8.1.3. SARS-CoV-2 (COVID-19) 8.1.4. Malaria 8.1.5. Pneumonia 8.1.6. Influenza 8.1.7. Herpes 8.1.8. Pertussis 8.1.9. Clostridium difficile infection 8.1.10. Other Disease 8.2. Environmental Inspection 8.3. Food Hygiene 8.4. Animal Husbandry 8.5. Fisheries 9. Asia Pacific Industry Analysis 2019 to 2023 and Forecast 2024 to 2034, by Purpose 9.1. Clinical Use 9.2. Research Purpose 10. Asia Pacific Industry Analysis 2019 to 2023 and Forecast 2024 to 2034, by End User 10.1. Hospital Laboratories 10.2. Academic & Research Institutes 10.3. Pharmaceutical & Biotechnology Companies 10.4. Diagnostic Laboratories 10.5. Food Testing Laboratories 10.6. Agricultural and Environmental Research Institutes 11. Asia Pacific Industry Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region 11.1. East Asia 11.2. South Asia & Pacific 12. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 13. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 14. Sales Forecast 2024 to 2034 by Product, Technology, Application, Purpose and End User for 11 Countries 15. Competition Outlook, including Industry Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 16. Company Profile 16.1. Eiken Chemical Co., Ltd. 16.2. New England Biolabs 16.3. HUMAN 16.4. Meridian Bioscience, Inc. 16.5. Thermo Fisher Scientific 16.6. Mast Group Ltd 16.7. Merck KGaA 16.8. Bio Rad Laboratories Inc. 16.9. QIAGEN N.V 16.10. Optigene 16.11. NIPPON GENE CO., LTD 16.12. ZENOSTIC 16.13. Jena Bioscience GmbH 16.14. Excellgen, Inc 16.15. Hologic Inc. (Gen-Probe) 16.16. LGC Ltd 16.17. Abbott Laboratories, Inc. 16.18. Yeasen Biotechnology (Shanghai) Co. Ltd. 16.19. highQu GmbH 16.20. Others
Explore Healthcare Insights
View Reports